Background: Systemic adenoviral (Ad) vector administration is associated with thrombocytopenia. Recently, Ad interaction with mouse platelets emerged as a key player determining liver uptake and platelet clearance. However, whether Ad can activate platelets is controversial. Thus, in vitro analysis of Ad attachment to platelets is of interest.
Background
Thrombocytopenia is a major adverse effect of high dose systemic administration of adenoviral (Ad) gene therapy vectors. While a previous report did not find platelet activation by Ad [1] , recent studies have shown that Ad may activate platelets [2] and binds in vivo to murine thrombo-cytes resulting in hepatic sequestration [3] . Ad-induced thrombocytopenia has been shown to be dose-dependent, saturable and reversible [4] , compatible with a ligand-receptor mechanism. Recently, binding of Ad to platelet was indirectly suggested following interference of platelet adhesion to fibronectin after incubation with Ad [2] . In this study we developed a direct flow cytometry assay to quantitatively analyze Ad attachment to human platelets in vitro and to characterize their interaction.
Many microorganisms in addition to Ad have evolved to facilitate cell entry via RGD recognition of cell surface integrins. For example, integrins mediate RGD-dependent attachment of picornaviruses [5, 6] and bacteria [7, 8] . In contrast, Group C Ad primarily attaches to the cell surface via the fiber protein knob binding to CAR [9] (coxsackie and Ad receptor). Next, Ad internalizes primarily utilizing V 3 integrin [10] , and to a lesser extent V 5 integrin [11] , via interaction of the RGD-containing Ad penton base protein. In addition to V 3 and V 5, other integrin receptors for Ad may include V 1, and 5 1 [12] . Because Ad uses both CAR and V integrins, we used our flow cytometry assay to evaluate CAR expression in platelets and integrin-mediated Ad binding to platelets.
Results

Human platelets bind Ad particles
To characterize attachment of Ad group C (serotype 5) to human platelets we employed a direct flow cytometry assay on human platelets using a FITC-labeled anti-Ad hexon antibody (see materials and methods section). First, we calibrated the system measuring Ad attachment to nucleated cells ( Fig. 1) , derived from isogenic human melanoma cell lines stably expressing either the Ad integrin receptor V 3 or the platelet integrin IIb 3 [13] . The specific integrin expression profile in these cells was confirmed with indirect flow cytometry (not shown). Ad binding to the cell surface of these cell lines (measured in 4°C) was similar, comprising two main populations, i.e. a small cell population binding Ad with high affinity and a larger population binding Ad with medium affinity ( Fig.  1a ). Of note, expression of the primary Ad attachment receptor, CAR, was practically absent in Mo cell lines (see below), thereby suggesting that surface integrins suffice to mediate Ad attachment in these cells. To discern in these nucleated cells cell surface Ad binding from infection, we also allowed cell entry (in 37°C) following infection with Ad encoding GFP (AdGFP) and measured transgene expression by direct flow cytometry (Fig. 1b) . These distinct flow cytometry assays could clearly differ between V-enhanced Ad cell entry ( Fig. 1b ) and V-independent Ad surface attachment ( Fig. 1a ).
Next, we employed direct flow cytometry to detect and characterize attachment of Ad to platelets. To this end, the unique flow cytometry appearance of platelets could allow their specific gating, further confirmed by platelet stain with anti-CD41 ( IIb 3), an integrin expressed uniquely in platelets ( Fig. 2a ). Human platelets were incubated with Ad, rinsed and incubated with FITC-labeled anti-Ad hexon antibody prior to flow cytometry. This strategy allowed quantitative identification of Ad particles adherent to the platelet surface ( Fig. 2c ). There was no cross-reactivity of FITC-labeled anti-Ad hexon antibody with human platelets (Fig. 2b ). Platelet activation by thrombin did not affect Ad attachment to platelets (Fig.  2d ), and Mn +2 supplementation marginally enhanced Ad attachment ( Fig. 2e ). However, combining Mn +2 supplementation with thrombin activation substantially enhanced Ad attachment to platelets (Fig. 2f) .
A previous report suggested that in vitro incubation of Ad with human platelets failed to aggregate platelets [1] . In contrast, systemic Ad injection could induce platelet activation in vivo [2, 3] and enhanced platelet clearance [4] . To clarify this issue we measured exteriorization of the platelet membrane phosphatidylserine using annexin stain (indicating apoptosis in nucleated cells but serving as a marker of activation in platelets [14] ) and observed that Ad could efficiently activate human platelets in vitro ( Fig.  2g ,h). To optimize the conditions of Ad-platelet binding we tested several MOIs and FITC anti-hexon antibody concentrations ( Fig. 3 ) and found that an MOI of 10 is optimal for Ad binding and that dilution of the FITC antihexon antibody resulted in a reduced Ad signal. Thus, Ad attachment to human platelets can be characterized in vitro using direct flow cytometry.
Ad virions adhere to the platelet surface
To discern between platelet cell entry vs. Ad attachment to the platelet membrane, we employed two methods. First, Ad was incubated with platelets either at 37°C or 4°C, the latter precluding cell entry [10] . In addition, Ad were incubated either with live or fixed platelets, the latter also precluding cell entry. Our data indicate that Ad-platelet interaction solely involves adherence to the cell surface ( Fig. 4a ). Confocal immunofluorescent microscopy qualitatively confirmed attachment of Ad virions to the platelet surface ( Fig. 4b ).
Ad binds to platelet surface integrins
Next, we employed flow cytometry to evaluate the mechanism of Ad binding to the platelet surface. Ad displaying an RGD ligand in the HI fiber knob loop adhered more efficiently to platelets than unmodified Ad ( Fig. 5a ) and a variety of RGD-based ligands could block Ad attachment to platelets ( Fig. 5b ). However, GRGDS (RGD) was less efficient vs. eptifibatide (a synthetic analog based on the barbourin motif, containing a homoArginine-Glycine-Aspartate sequence), or vs. the FBG carboxy terminus 400-411 dodecapetide (C ). These two peptides could efficiently (6-fold) block platelet Ad binding. A monoclonal anti-V 3 antibody could also specifically, but only partially, block Ad attachment to platelets ( Fig. 5c ). Because V 3 expression on platelets is minute [15] , these data may indicate a high affinity of Ad to platelet V 3. Of note, while previous studies showed a role for heparan sulfate proteoglycans in Ad binding to nucleated cells [12] , heparan sulfate does not appear to play a role in Ad binding to platelets as several doses of heparin did not block Ad attachment to platelets (not shown).
Expression of CAR, the primary Ad attachment receptor on nucleated cells, has been recently reported in platelets [2] . However, in our studies CAR expression was not detected on human platelets ( Fig. 6 ), confirmed by negative (Mo cells) and positive (HEK 293 cells) nucleated cell controls for CAR expression. Taken together, our data indicate a role for integrins in mediating Ad binding to human platelets in vitro.
Enhanced Ad attachment in Glanzmann Thrombasthenia platelets
We next sought to evaluate Ad binding to platelets deficient of the integrin IIb 3 (also called gpIIb/IIIa) from a patient with Glanzmann thrombasthenia (GT). GT mutations in the IIb 3 gene result in a bleeding tendency because IIb 3 expression is either abolished or the fibrinogen (FBG) binding domain is disrupted [1] . Consequently, platelet adhesion and aggregation are impaired, resulting in life-long bleeding diathesis. The mutation in the kindred to which this patient belongs comprises complete abolition of II expression while 3 expression is maintained to a small extent. Thus, a small degree of V 3 platelet expression may be preserved in GT [15] . We first confirmed that platelets from the patient with GT had practically no IIb 3 expression ( Fig. 7a ), and were functionally impaired as evident by both reduced platelet attachment to FBG ( Fig. 7b ) and decreased activation by thrombin (not shown). Surprisingly, GT platelets bound Ad 5-fold more efficiently than normal platelets ( Fig. 7c ).
Discussion
Platelets bind physiological ligands in an RGD-dependent manner, e.g. FBG, von Willerband factor (VWF), fibronec-tin and vitronectin. Non-physiological platelet integrin ligands include disintegrins (cyclic RGD-based polypeptides in snake venoms) and a number of microorganisms.
One of the most extensively characterized pathogens with respect to nucleated cellular integrin interaction is Ad. Cell entry by Ad viruses initially involves attachment of the Ad fiber knob to the primary Ad receptor, CAR [6] , followed simultaneously or subsequently by binding of any of the five RGD protrusions on the Ad penton base protein to cellular V integrins heterodimerized to specific chains [10, 11] . A critical requirement for Ad infection is the interaction of membrane V integrin with the RGDdisplaying Ad penton base. This interaction has been previously demonstrated via inhibition of Ad cell entry by RGD peptides and antibodies to V integrins [10, 16] .
Integrin receptors are heterodimers comprised of and subunits whose specific sequence and activation-dependent conformation determine their ligand affinity. The ligand motif for a number of integrins is based on an arginine-glycine-aspartate (RGD) sequence and variations on the RGD theme determine specific ligand-integrin recognition. For example, fibrinogen (FBG) binding to IIb 3 depends on prior inside-out signaling, resulting in platelet priming and conformational IIb 3 transition into a high-affinity state [17] .
In the current study, we developed a direct flow cytometry approach to characterize Ad binding to human platelets, focusing on platelet integrin-mediated binding. Optimization of the methodology could show a number of pertinent findings. First, Ad binding to human platelets can be manipulated in vitro by combining a divalent ion and thrombin activation (Fig. 2) . Second, Ad binding activates platelets in vitro (Fig. 2) . Third, an optimal MOI in the order of 10 ( Fig. 3) was observed for Ad attachment to the platelet surface (Fig. 4) . This optimal MOI is compatible with the ratio of 40 between the spherical surface areas of platelets and Ad, given respective diameters of ~3 m and 150 nm. Fourth, Ad attachment to human platelets is at Characterization of Ad binding to human platelets Figure 2 (see previous page) Characterization of Ad binding to human platelets. Platelets were isolated from platelet-rich plasma as described in Materials and Methods. Platelets were incubated with Ad (MOI = 10, 1 hr, RT), followed by a thorough rinse and incubation with a FITC-labeled anti-Ad hexon antibody (1:1 least partially mediated by platelet integrins, as evident by blocking assays using anti-V 3 monoclonal antibody and RGD peptidomimetics ( Fig. 5 ).
Fifth, although CAR was previously reported to be expressed in human platelets both at the level of RNA and using flow cytomtery [2] , our studies show CAR deficiency in normal human platelets (Fig. 6 ).
Because CAR mediates homotypic cell adhesion, it is generally present in specialized intracellular junctions, including the cardiac intercalated disk and the adherens junction of polarized epithelial cells [12] . Although CAR is abundantly expressed in epithelial cells during embryogenesis, its expression in adult mice is restricted to fewer cell types, contrasting with the homogeneous expression pattern of V-integrins [18] . Thus, in bone marrow hematopoeitic lineages CAR expression is minute [19, 20] . 
Optimization of conditions for platelet Ad binding
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Platelets Ad binds to human platelets integrin-dependently Figure 5 Ad binds to human platelets integrin-dependently. (a) Platelets were isolated, incubated with Ad (black) or AdRGD (red) (MOI = 10, RT) and stained with FITC-labeled anti-hexon antibody as above in Fig. 2. (b) Prior to incubation with AdRGD, platelet integrins were blocked (RT, 1-hr, 150 mg/ml) with the peptides GRGDS (RGD), eptifibatide (a synthetic RGD analog) or C (a 12-amino acids peptide derived from the carboxy terminus of the FBG chain). GRGES served as a negative control. (c) Platelets were first incubated with monoclonal anti-v 3 or anti-CD41 (= IIb 3) antibodies (at 5 or 25 mg/ml), prior to rinse and incubation with AdRGD, rinse and staining with anti-hexon antibody. *, p < 0.05 for inhibition of Ad attachment with anti-v 3 antibody. Representative images of at least 2 different experiments (n = 3 for each). [2] . In contrast, we confirmed specificity of the rabbit H-300 polyclonal anti-CAR antibody in both CAR-positive and negative cell lines prior to testing CAR expression in platelets. While variations in the specificity of the anti-CAR antibodies employed may account for the discrepancy between our results and Othman et al [2] , further studies are required to conclusively define CAR expression in human platelets. However, our blocking assays, along with the recent observation that Ad serotype 11 can efficiently bind to mouse platelets fiber-independently [21] , further highlight the role of platelet integrins as mediators of Ad binding. Other integrins expressed by platelets include a5b1 and a1b1 [22, 23] . While these are not well established as Ad receptors, the recent finding of Ad interference with C.
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Ad binding Counts * platelet adhesion to fibronectin [2] may suggest that Ad may also bind to the fibronectin receptor a5b1.
Previously, IIb 3 (gpIIb/IIIa), the primary platelet FBG receptor was reported to mediate platelet attachment of the intracellular bacterial microorganisms, chlamydia and borrelia. These studies employed blocking assays using abciximab (an anti-IIb 3 antibody) and RGD peptides [24] [25] [26] , at 4-400 fold higher blocking concentrations than employed in this study. However, while V 3 may partially mediate attachment of Ad to platelets (Fig. 5) , IIb 3 does not appear to play a significant role in Ad binding to platelets, as evident by lack of blockade by a monoclonal antibody against IIb 3 (Fig. 5) , and by avid adherence of Ad to IIb 3-deficient platelets from a patient with Glanzmann thrombasthenia (Fig. 7) . Of note, unlike borrelia binding to platelets that requires prior platelet activation [24, 25] , Ad could also efficiently bind to naïve platelets, although platelet activation along with MnCl enhanced Ad binding (Fig. 2) .
Glanzmann thrombasthenia (GT) is a rare, inherited disorder of platelet function characterized by mucocutaneous hemorrhage caused by mutations in the IIb 3 gene. The major laboratory finding in GT is a profound defect in platelet aggregation caused by a failure of IIb 3 to bind FBG. In this study we observed minute expression of IIb 3 on platelets from a patient with GT. A typical mutation in this patient's kindred was previously found to completely abolish II expression while a very low 3 (III ) expression level was still detected [15] . Thus, unlike other IIb 3 mutations in other GT kindreds where both II and 3 were completely absent, platelets from this GT subpopulation maintain the potential to express some V 3 [15] . In this context, while we failed to document substantial V 3 expression on normal platelets, Coller et al had measured ~100 V 3 receptors per platelet, i.e. 0.25% of the number of IIb 3 receptors per platelet [15] .
Our findings on platelet-Ad interaction in vitro may have implications on the biodistribution of Ad in vivo. Previously, partial platelet depletion did not alter Ad biodistribution and it was postulated that Ad attachment to platelets may occur only in a small fraction of platelets [24] . However, we speculate that blockade of platelet integrins in vivo will alter Ad biodistribution. Recently, attachment of Ad particles to platelets resulted in plateletleukocyte aggregates [3] , VWF and p-selectin-mediated thrombocytopenia [2] via clearance by the reticuloendothelial system and the complement pathway [27] . While this scenario may complicate Ad-based gene delivery, it may reflect an evolutionary-conserved defense mechanism allowing to efficiently clear circulating RGDdisplaying microorganisms such as Ad. In support of this hypothesis, RGD display on the Ad fiber knob, in addition to the natural RGD ligand on the Ad penton base, has been reported to result in paradoxically diminished systemic tissue distribution [16] . Thus, fundamental to future rationalized systemic Ad-based gene delivery endeavors in humans is the molecular characterization of Ad-platelet interaction in vivo. Additionally, Ad biodistribution and toxicity may differ in GT patients from healthy subjects.
Taken together, we report a direct flow cytometry assay to characterize Ad binding to platelets. This approach may eventually be employed to determine the exact integrin profile accounting for Ad attachment to human platelets and therefore may have implications on systemic Ad biodistribution.
Methods
Adenoviral vectors
Ad vectors used in the attachment studies were E1/E3 deleted, replication-deficient serotype 5 Ad vectors. Ad-RGD vector is a caspid-modified Ad, displaying a CDCRGDCDC ligand in the Ad capsid fiber (both from David T. Curiel, University of Alabama at Birmingham). Vector titer was determined by both plaque forming units (PFU) and by spectrophotometric measurement of DNA optical density at 260 nm. The PFU/viral particle ratio was 100 for the Ad vectors.
Attachment assays
All attachment studies were performed in suspension after initial blocking with BSA. Antibody and peptide blocking assays were performed at 4°C (room temperature [RT] for platelets) with pre-incubation for 1-hr at 5 and 25 g/ml or 150 g/ml, respectively, as previously described to block cellular V integrins [10, 11] . Next, cells were rinsed, incubated with Ad for 1-hr, rinsed and processed for flow cytometry after incubation on ice with FITC-labeled anti-Ad hexon antibody for 1-hr. Attachment of Ad particles to the various Mo cell lines was measured after detaching cells by minimal trypsinization, rinse, resuspension (1 × 10 6 ) in serum-free medium, incubation with Ad (MOI = 10) at 4°C for 1-hr, rinse and incubation with FITC antihexon antibody for 1-hr on ice followed by processing for flow cytometry. Specificity of Ad attachment was confirmed via omission of Ad.
